The Los Angeles Post

Pfizer anticipates billions in less revenue this year

by ·

Pfizer executives said the company expects a significant drop in revenue in 2023 compared to 2022 as the U.S. government ends its purchase agreement for COVID-19 vaccines and treatments.

 

During its 2022 fourth quarter earnings call Tuesday, CEO Albert Bourla said he anticipates 2023 to be a “transition year,” as advance government purchases end and the company’s COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid start to become available on the commercial market.

 

Pfizer executives have not officially disclosed what the company will charge for its vaccine on the commercial market, but have previously said it could be between $110 and $130 a dose.

 

Pfizer said 2022 was a record-breaking year, as it generated nearly $57 billion in combined sales of its COVID-19 products.

  • The company’s COVID-19 windfall shows just how reliant it was on federal government contracts.
  • Pfizer anticipates $13.5 billion in sales for its vaccine this year, a decrease of 64 percent from 2022.
  • The pharmaceutical giant said it anticipates just $8 billion in Paxlovid revenue, down 58 percent from 2022.